Literature DB >> 8899817

Differential biotransformation of dynorphin A (1-17) and dynorphin A (1-13) peptides in human blood, ex vivo.

J Z Chou1, B T Chait, R Wang, M J Kreek.   

Abstract

The biotransformation in human blood in vitro of three dynorphin A (Dyn A) peptides was studied by matrix assisted laser desorption mass spectrometry to determine whether the natural peptide, Dyn A(1-17), is biotransformed differently from Dyn A (1-13), the natural sequence shortened form used in numerous neurobiological and pharmacological studies. In addition to studies of Dyn A(1-17), a natural product from prodynorphin and Dyn A(1-13), a natural sequence truncation of Dyn A(1-17), Dyn A(1-10)amide, a synthetic analogue of Dyn A(1-17) presumed to be protected from rapid biotransformation was also studied Synthetic Dyn A peptides were incubated in freshly drawn blood for various periods of time prior to mass spectrometric analysis. Several peptide products were identified from each precursor; the time profiles of appearance and disappearance of the major products were followed. Substantial differences in products and especially in the rate of biotransformation were observed between the processing of Dyn A(1-17) and the two shorter Dyn A peptides, Dyn A(1-13) and Dyn A(1-10)amide. Significant amounts of the natural Dyn A(1-17) survived 4 h of incubation (half-life 3 h). Dyn A (2-17), a major processed product of Dyn A(1-17) in blood, continued to accumulate during the 4-h incubation period. By contrast, both Dyn A(1-13) and Dyn A(1-10) amide were biotransformed very rapidly with half-lives of < 1 min and 10 min, respectively. Most of the products from these two peptide precursors were also further processed rapidly, with the exception of Dyn A(4-12) and Dyn A(4-10)amide, which were detected for over 2 h. Dyn A(1-6) was found as a minor biotransformation product from all three precursor peptides. These findings suggest that an important function of the four C-terminal amino acid residues of the natural form, Dyn A(1-17) [compared to Dyn A(1-13)], is to stabilize or protect the peptide from biotransformation by enzymes, by preserving a natural hairpin structure possibly near the carboxyl-terminus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8899817     DOI: 10.1016/0196-9781(96)00154-4

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  10 in total

1.  Regional quantitation of preprodynorphin mRNA in guinea pig gastrointestinal tract.

Authors:  V P Yuferov; J A Culpepper-Morgan; K S LaForge; A Ho; M J Kreek
Journal:  Neurochem Res       Date:  1998-04       Impact factor: 3.996

2.  Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.

Authors:  M Hiramatsu; K Inoue; A Ambo; Y Sasaki; T Kameyama
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Evaluation of an on-capillary copper complexation methodology for the investigation of in vitro metabolism of dynorphin A 1-17.

Authors:  Courtney D Kuhnline; Susan M Lunte
Journal:  J Sep Sci       Date:  2010-08       Impact factor: 3.645

4.  Dynorphin peptides differentially regulate the human kappa opioid receptor.

Authors:  Yong Chen; Chongguang Chen; Lee-Yuan Liu-Chen
Journal:  Life Sci       Date:  2007-01-20       Impact factor: 5.037

Review 5.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

6.  The permeation of dynorphin A 1-6 across the blood brain barrier and its effect on bovine brain microvessel endothelial cell monolayer permeability.

Authors:  Courtney D Kuhnline Sloan; Kenneth L Audus; Jane V Aldrich; Susan M Lunte
Journal:  Peptides       Date:  2012-10-06       Impact factor: 3.750

Review 7.  Peptide kappa opioid receptor ligands: potential for drug development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

Review 8.  Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity.

Authors:  Maryam Eskandari Mehrabadi; Roohullah Hemmati; Amin Tashakor; Ahmad Homaei; Masoumeh Yousefzadeh; Karim Hemati; Saman Hosseinkhani
Journal:  Biomed Pharmacother       Date:  2021-02-05       Impact factor: 7.419

Review 9.  Opioids, dopamine, stress, and the addictions.

Authors:  Mary Jeanne Kreek
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

Review 10.  2',6'-dimethylphenylalanine: a useful aromatic amino Acid surrogate for tyr or phe residue in opioid peptides.

Authors:  Yusuke Sasaki; Akihiro Ambo
Journal:  Int J Med Chem       Date:  2012-04-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.